MAPT and migraine disorder: Notably, CGRPr antagonists that are approved for migraine treatment (e.g., erenumab, gepants) have demonstrated neuroprotective effects in AD mouse models, reducing amyloid-β deposition and tau pathology while enhancing cognitive performance27,28.